Published by Michele Maatouk on 9th August 2024
(Sharecast News) - Merck said on Friday that it has agreed to buy biotech firm Curon's CN201, a novel investigational clinical-stage bispecific antibody for the treatment of B-cell associated diseases, for up to $1.3bn.
URL: http://www.digitallook.com/dl/news/story/34483834/...